GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (NAS:ORGS) » Definitions » PS Ratio

Orgenesis (Orgenesis) PS Ratio : (As of Apr. 26, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Orgenesis PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Orgenesis's share price is $0.5071. Orgenesis's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.17. Hence, Orgenesis's PS Ratio for today is .

Warning Sign:

Orgenesis Inc stock PS Ratio (=28) is close to 5-year high of 28

The historical rank and industry rank for Orgenesis's PS Ratio or its related term are showing as below:

During the past 13 years, Orgenesis's highest PS Ratio was 41.27. The lowest was 0.37. And the median was 4.56.

ORGS's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 8.92
* Ranked among companies with meaningful PS Ratio only.

Orgenesis's Revenue per Sharefor the three months ended in Dec. 2023 was $-0.42. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.17.

Warning Sign:

Orgenesis Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Orgenesis was -98.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was -63.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was -34.90% per year.

During the past 13 years, Orgenesis's highest 3-Year average Revenue per Share Growth Rate was 80.30% per year. The lowest was -63.10% per year. And the median was -14.10% per year.

Back to Basics: PS Ratio


Orgenesis PS Ratio Historical Data

The historical data trend for Orgenesis's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis PS Ratio Chart

Orgenesis Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.02 12.53 1.97 1.36 27.82

Orgenesis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.36 1.03 1.27 0.79 27.82

Competitive Comparison of Orgenesis's PS Ratio

For the Biotechnology subindustry, Orgenesis's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orgenesis's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orgenesis's PS Ratio distribution charts can be found below:

* The bar in red indicates where Orgenesis's PS Ratio falls into.



Orgenesis PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Orgenesis's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.5071/-0.167
=

Orgenesis's Share Price of today is $0.5071.
Orgenesis's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.17.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Orgenesis  (NAS:ORGS) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Orgenesis PS Ratio Related Terms

Thank you for viewing the detailed overview of Orgenesis's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Orgenesis (Orgenesis) Business Description

Traded in Other Exchanges
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Morgenesis and Therapies.
Executives
Elliot Maltz officer: Chief Financial Officer C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Jacob Safier 10 percent owner C/O THE WOLFSON GROUP, ONE STATE STREET PLAZA 29TH FLOOR, NEW YORK NY 10004
Efrat Assa Kunik officer: Chief Development Officer C/O ORGENESIS INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
David Sidransky director JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205
Mario Philips director C/O ATMI, INC, DANBURY CT 06810
Sarah Ferber officer: Chief Scientific Officer 17B HAHASKALA STREET, TEL AVIV L3 67890
Guy Yachin director 7 ORCHARD WAY N, POTOMAC MD 20854
Yaron Adler director 4 HA'NECHOSHET ST., RAMAT HA'CHAYAL, TEL AVIV L3 69710
Vered Caplan officer: CEO 20 HA'ETZEL STREET, PO BOX 9118 RAMAT EFAL, KIRYAT ONO L3 55280
Universite Libre De Bruxelles 10 percent owner AVENUE F, ROOSEVELT, 50, BRUSSELS C9 1050
Olivier Belenger 10 percent owner DIEWEG, 69, BRUSSELS C9 1070
Ii Sa Theodorus 10 percent owner ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Sca Theodorus 10 percent owner ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Denis Bedoret officer: See Remarks 48, RUE AUGUSTE PICCARD, GOSSELIES C9 6041
Ashish Nanda director 2301, 23RD FLOOR, TIFFANY TOWERS, CLUSTER W, JLT, DUBAI, UAE, DUBAI C0 4452